- Home
- XYLO vs SONN Comparison
XYLO vs SONN Comparison
Compare XYLO & SONN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XYLO
- SONN
- Stock Information
- Founded
- XYLO 1999
- SONN N/A
- Country
- XYLO Israel
- SONN United States
- Employees
- XYLO N/A
- SONN N/A
- Industry
- XYLO
- SONN Biotechnology: Pharmaceutical Preparations
- Sector
- XYLO
- SONN Health Care
- Exchange
- XYLO NYSE
- SONN Nasdaq
- Market Cap
- XYLO 2.3M
- SONN 2.5M
- IPO Year
- XYLO N/A
- SONN N/A
- Fundamental
- Price
- XYLO $3.15
- SONN $1.61
- Analyst Decision
- XYLO
- SONN Strong Buy
- Analyst Count
- XYLO 0
- SONN 2
- Target Price
- XYLO N/A
- SONN $148.00
- AVG Volume (30 Days)
- XYLO 17.6K
- SONN 2.7M
- Earning Date
- XYLO 12-27-2024
- SONN 12-17-2024
- Dividend Yield
- XYLO N/A
- SONN N/A
- EPS Growth
- XYLO N/A
- SONN N/A
- EPS
- XYLO N/A
- SONN N/A
- Revenue
- XYLO $57,642,000.00
- SONN $18,626.00
- Revenue This Year
- XYLO N/A
- SONN N/A
- Revenue Next Year
- XYLO N/A
- SONN N/A
- P/E Ratio
- XYLO N/A
- SONN N/A
- Revenue Growth
- XYLO N/A
- SONN N/A
- 52 Week Low
- XYLO $2.70
- SONN $1.57
- 52 Week High
- XYLO $10.43
- SONN $18.72
- Technical
- Relative Strength Index (RSI)
- XYLO 39.41
- SONN 24.41
- Support Level
- XYLO $3.11
- SONN $1.73
- Resistance Level
- XYLO $3.90
- SONN $1.94
- Average True Range (ATR)
- XYLO 0.31
- SONN 0.48
- MACD
- XYLO -0.05
- SONN 0.03
- Stochastic Oscillator
- XYLO 2.94
- SONN 1.22
About XYLO XYLO TECHNOLOGIES LTD
Xylo Technologies Ltd is an Israel-based medical device company. The company is engaged in the development, manufacturing, and marketing of direct vision systems for minimally invasive medical procedures and safety systems for drones and the electric vehicle (EV) sector. The key product of the company is the MUSE (Medigus Ultrasonic Surgical Endostapler) system is a single-use device for the incision-less treatment of GERD (gastroesophageal reflux disease), which is based on proprietary platform technology and know-how. The company operates in five segments namely, E-Commerce, Online Advertising & Internet Traffic Routing, Online Event Management, Corporate, and others. The company's geographical segments include the United States, Europe, Great Britain, Israel, Canada, Asia, and others.
About SONN Sonnet BioTherapeutics Holdings Inc.
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.